Bionik Laboratories Corp.
BNKL
$0.0001
$0.000.00%
| 03/31/2023 | 12/31/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -12.87% | 18.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.87% | 18.28% | |||
| Cost of Revenue | -18.88% | 61.45% | |||
| Gross Profit | -6.10% | -9.07% | |||
| SG&A Expenses | 6.01% | 3.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.89% | 1.32% | |||
| Operating Income | -19.33% | 6.10% | |||
| Income Before Tax | -26.03% | 4.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.03% | 4.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.03% | 4.71% | |||
| EBIT | -19.33% | 6.10% | |||
| EBITDA | -19.72% | 6.84% | |||
| EPS Basic | -24.30% | 4.75% | |||
| Normalized Basic EPS | -19.53% | 4.68% | |||
| EPS Diluted | -24.30% | 4.75% | |||
| Normalized Diluted EPS | -19.53% | 4.68% | |||
| Average Basic Shares Outstanding | 1.40% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.40% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
